HTG Molecular Diagnostics Inc (HTGM) was Initiated by Rodman & Renshaw to “Buy” and the brokerage firm has set the Price Target at $5. Rodman & Renshaw advised their investors in a research report released on Aug 22, 2016.
HTG Molecular Diagnostics Inc (HTGM) witnessed a volatile trading activity on Friday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $2.45 and reached the intraday high at $2.57. The bulls started the profit booking and pushed the shares to intraday low of $2.41. The trading session was marked by a volume range of 7,965 shares exchanging hands. The 52-week high of the shares is $13.1 and the 52-week low is $2.03. The market cap of the company stands at $17 M and there are 70,50,957 shares in public circulation.
In a different news, on Apr 5, 2016, Debra A Gordon (V.P. and Chief Legal Counsel) sold 1,672 shares at $2.91 per share price. According to the SEC, on Apr 5, 2016, Shaun D Mcmeans (VP, Finance & Admin. & CFO) sold 1,601 shares at $2.91 per share price. On Apr 5, 2016, John L Lubniewski (Chief Business Officer) sold 796 shares at $2.91 per share price, according to the Form-4 filing with the securities and exchange commission.
HTG Molecular Diagnostics Inc is a United States-based company that provides products for miRNA and mRNA measurement for translational research/medicine and molecular diagnostics. Its qNPA molecular technology platform is suited for detecting changes in gene expression levels; especially from formalin-fixed paraffin-embedded (FFPE) tissue and other biological sample types. Its products include HTG Edge System HTG Edge Assays and HTG Assay Direct. The HTG Edge System an automated RNA analysis platform that delivers extraction-free multiplexed results on a multitude of biological samples (tissue blood serum cells) in less than 24 hours. HTG Edge DMPK Assay is a 47-gene assay that enables researchers to characterize drug metabolism in pre-clinical studies. HTG Edge Top Oncogene Assay measures the expression levels of 32 of the most commonly assayed oncogenes in fresh or fixed biological specimens.